(DRTS) Alpha Tau Medical - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.004m USD | Total Return: 234.7% in 12m
Avg Turnover: 7.65M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Share dilution 22.2% YoY
Altman Z'' -7.22 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Alpha Tau Medical Ltd. (DRTS) is a Jerusalem-based clinical-stage biotechnology firm specializing in the development of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). The proprietary technology utilizes the intra-tumoral delivery of alpha-emitting isotopes to treat solid tumors while aiming to spare surrounding healthy tissue. The company’s clinical pipeline currently spans multiple indications, including skin, oral, pancreatic, and breast cancers, alongside ongoing preclinical research into various human-derived tumor models.
The oncology sector increasingly focuses on localized radiation therapies to minimize the systemic toxicity associated with traditional external beam radiation. Alpha particles are characterized by high linear energy transfer, which causes dense ionization tracks capable of inducing irreparable double-strand DNA breaks in malignant cells. Reviewing the complete clinical trial data on ValueRay can provide deeper insights into the efficacy of these targeted treatments. As a clinical-stage entity, Alpha Tau’s business model relies on the successful progression of its candidates through regulatory phases toward commercialization and potential licensing agreements.
- FDA approval timeline for Alpha DaRT pivotal trial determines market entry
- Clinical trial data readouts for multiple solid tumor indications drive valuation
- Strategic partnerships for global manufacturing and distribution scale revenue potential
- High R&D expenditure and cash burn rate impact short-term liquidity
- Geopolitical instability in Israel poses operational and supply chain risks
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -19.21 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -26.7m > Net Income -42.6m |
| Net Debt (-55.8m) to EBITDA (18.3m): -3.05 < 3 |
| Current Ratio: 7.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (85.7m) vs 12m ago 22.22% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: 40.77 > 6 (EBITDA TTM 18.3m / Interest Expense TTM 419k) |
| A: 0.64 (Total Current Assets 78.3m - Total Current Liabilities 10.5m) / Total Assets 106.6m |
| B: -1.78 (Retained Earnings -190.1m / Total Assets 106.6m) |
| C: 0.18 (EBIT TTM 17.1m / Avg Total Assets 96.4m) |
| D: -6.45 (Book Value of Equity -190.1m / Total Liabilities 29.5m) |
| Altman-Z'' = -7.22 = D |
As of May 24, 2026, the stock is trading at USD 10.96 with a total of 714,634 shares traded.
Over the past week, the price has changed by -3.09%,
over one month by +24.26%,
over three months by +37.35% and
over the past year by +234.67%.
Alpha Tau Medical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy DRTS.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.5 | 4.9% |
Revenue TTM = 0.0 USD
EBIT TTM = 17.1m USD
EBITDA TTM = 18.3m USD
Long Term Debt = 6.35m USD (from longTermDebt, last quarter)
Short Term Debt = 1.13m USD (from shortTermDebt, last quarter)
Debt = 21.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.37m
Net Debt = -55.8m USD (calculated: Debt 21.1m - CCE 76.9m)
Enterprise Value = 947.9m USD (1.00b + Debt 21.1m - CCE 76.9m)
Interest Coverage Ratio = 40.77 (Ebit TTM 17.1m / Interest Expense TTM 419k)
EV/FCF = -19.97x (Enterprise Value 947.9m / FCF TTM -47.5m)
FCF Yield = -5.01% (FCF TTM -47.5m / Enterprise Value 947.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.23m) / Revenue TTM)
Tobins Q-Ratio = 8.89 (Enterprise Value 947.9m / Total Assets 106.6m)
Interest Expense / Debt = 1.99% (Interest Expense 419k / Debt 21.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = 13.5m (EBIT 17.1m * (1 - 21.00%))
Current Ratio = 5.45 (Total Current Assets 78.3m / Total Current Liabilities 14.4m)
Debt / Equity = 0.27 (Debt 21.1m / totalStockholderEquity, last quarter 77.1m)
Debt / EBITDA = -3.05 (Net Debt -55.8m / EBITDA 18.3m)
Debt / FCF = 1.18 (negative FCF - burning cash) (Net Debt -55.8m / FCF TTM -47.5m)
Total Stockholder Equity = 74.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.22% (Net Income -42.6m / Total Assets 106.6m)
RoE = -16.11% (Net Income TTM -42.6m / Total Stockholder Equity 264.5m)
RoCE = 6.31% (EBIT 17.1m / Capital Employed (Equity 264.5m + L.T.Debt 6.35m))
RoIC = 13.88% (NOPAT 13.5m / Invested Capital 97.2m)
WACC = 10.17% (E(1.00b)/V(1.02b) * Re(10.35%) + D(21.1m)/V(1.02b) * Rd(1.99%) * (1-Tc(0.21)))
Discount Rate = 10.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 9.76%
[DCF] Fair Price = unknown (Cash Flow -47.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.40 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.14 | Chg30d=-12.99% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.14 | Chg30d=-10.67% | Revisions=-33% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.66 | Chg30d=-29.26% | Revisions=-25% | GrowthEPS=-24.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.45 | Chg30d=-6.25% | Revisions=-43% | GrowthEPS=+31.4% | GrowthRev=+908.9%
[Analyst] Revisions Ratio: -43%